# RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

> **NCT06385873** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 32 (estimated)

## Conditions studied

- Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** RC48
- **DRUG:** Adebrelimab
- **DRUG:** Apatinib
- **DRUG:** S-1

## Key facts

- **NCT ID:** NCT06385873
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2027-05-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2024-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06385873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06385873, "RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT06385873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*